Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06611371 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.
A Phase 1 study of Group B Streptococcal Infections, sponsored by Inventprise.
- Active
- Registry status
- Phase 1
- Development phase
- 600
- Enrollment target
- 2
- Study locations
NCT06611371 is a Phase 1 study of Group B Streptococcal Infections that is active but no longer recruiting, run by Inventprise. The registered enrollment target is 600 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06611371, a Phase 1 study of Group B Streptococcal Infections, is active but no longer recruiting, sponsored by Inventprise.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 600 participants
- Enrollment target
- 2
- Study locations
Study Summary
To assess the safety and tolerability of IVT GBS-06 vaccine administered as a single-dose regimen, at three dosage levels in healthy, non-pregnant, adult women of childbearing age (WOCBA).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL IVT GBS-06
Study Locations (2)
New York
- NYU Grossman School of Medicine - New York
Gauteng
- Wits Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), University of the Witwatersrand - Johannesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-11-12 |
| Est. Completion | 2026-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06611371
The ClinicalTrials.gov registry entry for NCT06611371 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inventprise, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Group B Streptococcal Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06611371 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Gauteng.
Frequently Asked Questions
What is clinical trial NCT06611371 about?
NCT06611371 is a clinical study titled "Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.". To assess the safety and tolerability of IVT GBS-06 vaccine administered as a single-dose regimen, at three dosage levels in healthy, non-pregnant, adult women of childbearing age (WOCBA).
What is the current status of trial NCT06611371?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 600 participants. The study started on 2024-11-12. Estimated completion is 2026-02.
What conditions does trial NCT06611371 study?
This clinical trial studies the following conditions: Group B Streptococcal Infections.
What interventions are being tested in trial NCT06611371?
The interventions under investigation include: Placebo (BIOLOGICAL), IVT GBS-06 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06611371?
This trial is sponsored by Inventprise, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06611371 being conducted?
This trial has 2 study locations across New York, Gauteng. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.